In March of 2018, Aqilion AB (formerly Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB) carried out a directed issue of units.

Each unit consisted of one share and two warrants. At that time, Aqilion raised SEK 100 million through subscription for shares. All outstanding warrants have now been converted to shares, which raised an additional SEK 100 million for the company.

The issue was carried out to fund the restructuring of Aqilion’s strategy and organization, as well as the development of current and new pharmaceutical projects in the pipeline.

“It is extremely rewarding that the entire issue of units is completed and fully subscribed. It means that, with the support of Aqilion’s owners and the Board of Directors, we can continue to develop the project portfolio and increase the value of the company. On behalf of the entire team, I am both grateful and proud to be entrusted with this mission. With a new organization and funding lined up, we have created the optimum conditions to focus on efficiently developing our business model and our pharmaceutical projects,” says Sarah Fredriksson, CEO of Aqilion.

Photo of Sarah Fredriksson: Aqilion